We are live on ! Find out more
XBIT icon

XBiotech
XBIT

39 hedge funds and large institutions have $14.2M invested in XBiotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $3K | Put options by funds: $1K

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

5% more funds holding

Funds holding: 37 → 39 (+2)

2% more capital invested

Capital invested by funds: $14M → $14.2M (+$250K)

0.71% more ownership

Funds ownership: 10.98% → 11.69% (+0.71%)

Holders
39
Holders Change
+2
Holders Change %
+5.41%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
14
Reduced
8
Closed
3
Calls
$3K
Puts
$1K
Net Calls
+$2K
Net Calls Change
+$24K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$533K
2
Man Group
Man Group
United Kingdom
+$232K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$215K
4
Northern Trust
Northern Trust
Illinois
+$105K
5
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$97K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$540K
2
Renaissance Technologies
Renaissance Technologies
New York
-$63K
3
Two Sigma Investments
Two Sigma Investments
New York
-$21.5K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$20.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
TNB
26
Thomasville National Bank
Georgia
$53.4K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$49.1K +$6.46K +1,621 +15%
SF
28
Synovus Financial
Georgia
$47.2K – – –
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$45.3K +$1.99K +500 +5%
Charles Schwab
30
Charles Schwab
California
$41.9K – – –
LFM
31
LGT Fund Management
Liechtenstein
$39.7K – – –
UBS Group
32
UBS Group
Switzerland
$37.8K +$16.6K +4,172 +79%
ME
33
McIlrath & Eck
Washington
$3.01K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$3.01K – – –
Simplex Trading
35
Simplex Trading
Illinois
$2K +$1.84K +462 +282%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$1K -$4.57K -1,147 -80%
Wells Fargo
37
Wells Fargo
California
$608 +$32 +8 +6%
TRCT
38
Tower Research Capital (TRC)
New York
$208 +$207 +52 New
JP Morgan Chase
39
JP Morgan Chase
New York
$152 – – –
Renaissance Technologies
40
Renaissance Technologies
New York
– -$63K -15,287 Closed
Group One Trading
41
Group One Trading
Illinois
– -$7.16K -1,738 Closed
Osaic Holdings
42
Osaic Holdings
Arizona
– -$206 -50 Closed
1
2

XBIT Hedge Fund Activity: Q4 2023 in Review

39 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2023, worth a combined $14.2M — up 1.8% from $14M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new XBIT positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $533K. The largest seller was Millennium Management, cutting an estimated $540K.

  • 39 institutional investors held XBiotech (XBIT) as of Q4 2023, up from 37 in Q3 2023.
  • Funds reported $14.2M of XBiotech stock for Q4 2023, up 1.8% quarter-over-quarter.
  • 5 funds opened new XBiotech positions in Q4 2023 and 3 closed out, a net change of +2 holders.
  • The largest XBiotech buyer in Q4 2023 was Morgan Stanley, an estimated $533K added.
  • The largest XBiotech seller in Q4 2023 was Millennium Management, an estimated $540K sold.

Based on aggregated 13F filings for Q4 2023.